Sequential adrlamycin (A), docetaxel (D) and CMF in the adjuvant treatment (AT) of breast cancer (BC)

In preparationfor a phase III trial evaluatingD and dose-intensityin the AT of BC. we studiedthe feasibilityof these regimens: 1) non-accelerated (NA): A 75 m9'm2 q 3 wks )( 3-0 100 m9'm2 q 3 wks )( 3 -+ CMF days 1. 8 q 4 wks )( 3; 2) accelerated (ACC): A 75 m9'm2 q2 wks + lenograstlm(G) )( 3 -+ 0 100 mg/m2 q2 wks + G )( 3 -+ CMF (as NA). Radiotherapywas givendurin9'afterCMF. 48 pts are evaluable:19 treated with NA and 29 with ACC. Pt characteristicsare: median age 48 (29-66), stage IVIII untreatedBC 4315. 164 and 165 cycleswere deliveredso far in NA and ACC. respectively.Median relativeclose-intensityis 100% In both arms. Skin toxicityoccurred in 62% 01 pIs receivingACC (17% G~4) andconsistedoferythematousplaquesindifferentbodyareas. Skinlesions appeared duringtrealmentwithA in 24% of cases.